Background
Methods
Quality of care assessment
Statistical analysis
Results
Clinical characteristics of T2DM participants according to age
All |
< 65 years
|
65–75 years
|
> 75 years
| |
---|---|---|---|---|
n = 157,595
|
n = 58,238
|
n = 56,682
|
n = 42,675
| |
Male sex | 89,290 (56.7%) | 35,941 (61.7%) | 32,469 (57.3%) | 20,880 (48.9%) |
Age (years) | 68 ± 11 | 57 ± 7 | 70 ± 3 | 80 ± 4 |
Known duration of diabetes (years) | 11 ± 9 | 8 ± 7 | 12 ± 9 | 15 ± 11 |
Serum creatinine (mg/dL) | 0.98 ± 0.54 | 0.88 ± 0.43 | 0.99 ± 0.54 | 1.10 ± 0.63 |
eGFR (mL/min/1.73m2) | 76 ± 21 | 89 ± 18 | 74 ± 18 | 62 ± 19 |
Retinopathy | 22,250 (14.1%) | 6998 (12.0%) | 8773 (15.5%) | 6479 (15.2%) |
BMI (Kg/m2) | 29.6 ± 5.3 | 30.4 ± 5.8 | 29.6 ± 5.1 | 28.4 ± 4.7 |
HbA1c (%) | 7.2 ± 1.3 | 7.3 ± 1.4 | 7.2 ± 1.2 | 7.2 ± 1.2 |
HbA1c | ||||
7.0–7.4% | 26,576 (17.1%) | 9002 (15.7%) | 10,057 (18.0%) | 7517 (17.9%) |
7.5–8.5% | 32,320 (20.8%) | 11,265 (19.7%) | 11,473 (20.5%) | 9582 (22.8%) |
> 8.5% | 20,993 (13.5%) | 9214 (16.1%) | 6401 (11.4%) | 5378 (12.8%) |
Total cholesterol (mg/dL) | 177 ± 39 | 181 ± 40 | 175 ± 37 | 176 ± 38 |
Triglycerides (mg/dL) | 137 ± 90 | 147 ± 108 | 133 ± 82 | 128 ± 69 |
HDL (mg/dL) | 50 ± 14 | 48 ± 14 | 50 ± 14 | 51 ± 15 |
LDL (mg/dL) | 101 ± 33 | 104 ± 34 | 99 ± 32 | 100 ± 33 |
Systolic BP (mmHg) | 137 ± 18 | 134 ± 18 | 139 ± 18 | 140 ± 19 |
Diastolic BP (mmHg) | 78 ± 9 | 79 ± 9 | 78 ± 9 | 76 ± 9 |
Smokers | 14,793 (16.7%) | 8865 (25.2%) | 4435 (14.1%) | 1493 (6.9%) |
Cardiovascular therapy | ||||
Lipid-lowering treatment | 90,690 (57.5%) | 31,402 (53.9%) | 35,490 (62.6%) | 23,798 (55.8%) |
Treatment with statins | 83,342 (52.9%) | 28,002 (48.1%) | 32,928 (58.1%) | 22,412 (52.5%) |
Treatment with fibrates | 4588 (2.9%) | 2285 (3.9%) | 1503 (2.7%) | 800 (1.9%) |
Antihypertensive treatment | 112,424 (71.3%) | 35,069 (60.2%) | 43,031 (75.9%) | 34,324 (80.4%) |
Treatment with ACE-Is/ARBs | 95,821 (60.8%) | 30,460 (52.3%) | 36,938 (65.2%) | 28,423 (66.6%) |
Aspirin | 35,284 (22.4%) | 9467 (16.3%) | 14,278 (25.2%) | 11,539 (27.0%) |
Antidiabetic therapy | ||||
Diet | 8229 (5.2%) | 3149 (5.4%) | 3086 (5.4%) | 1994 (4.7%) |
Oral antidiabetic drugs | 100,535 (63.8%) | 39,150 (67.2%) | 36,379 (64.2%) | 25,006 (58.6%) |
Oral antidiabetic drugs and insulin | 26,634 (16.9%) | 9460 (16.2%) | 9906 (17.5%) | 7268 (17.0%) |
Insulin | 22,197 (14.1%) | 6479 (11.1%) | 7311 (12.9%) | 8407 (19.7%) |
Q Score | 30 ± 8 | 30 ± 8 | 30 ± 8 | 29 ± 8 |
< 15 | 5935 (3.8%) | 2534 (4.4%) | 1808 (3.2%) | 1593 (3.7%) |
15–25 | 42,165 (26.8%) | 15,375 (26.4%) | 14,447 (25.5%) | 12,343 (28.9%) |
> 25 | 109,495 (69.5%) | 40,329 (69.2%) | 40,427 (71.3%) | 28,739 (67.3%) |
Clinical characteristics of T2DM participants according to age and the presence of low eGFR and albuminuria
< 65 years
|
65–75 years
|
> 75 years
| |||||||
---|---|---|---|---|---|---|---|---|---|
eGFR-
|
eGFR+
|
eGFR-
|
eGFR+
|
eGFR-
|
eGFR+
| ||||
n = 54,297
|
n = 3941
|
p
|
n = 44,378
|
n = 12,304
|
p
|
n = 23,754
|
n = 18,921
|
p
| |
Male sex |
33,640 (62.0%)
|
2301 (58.4%)
|
< 0.001
|
25,773 (58.1%)
|
6696 (54.4%)
|
< 0.001
|
12,262 (51.6%)
|
8618 (45.5%)
|
< 0.001
|
Age (years) |
56 ± 7
|
60 ± 5
|
< 0.001
|
70 ± 3
|
71 ± 3
|
< 0.001
|
80 ± 4
|
81 ± 4
|
< 0.001
|
Duration of diabetes (years) |
8 ± 7
|
11 ± 9
|
< 0.001
|
11 ± 9
|
14 ± 9
|
< 0.001
|
14 ± 10
|
16 ± 11
|
< 0.001
|
Albuminuria |
13,031 (24.0%)
|
1855 (47.1%)
|
< 0.001
|
11,126 (25.1%)
|
5000 (40.6%)
|
< 0.001
|
6770 (28.5%)
|
7605 (40.2%)
|
< 0.001
|
Retinopathy |
6073 (11.2%)
|
925 (23.5%)
|
< 0.001
|
6208 (14.0%)
|
2565 (20.8%)
|
< 0.001
|
3168 (13.3%)
|
3311 (17.5%)
|
< 0.001
|
BMI (Kg/m2) |
30.3 ± 5.7
|
31.8 ± 6.2
|
< 0.001
|
29.3 ± 5.0
|
30.5 ± 5.3
|
< 0.001
|
28.0 ± 4.6
|
28.8 ± 4.8
|
< 0.001
|
HbA1c (%) |
7.3 ± 1.4
|
7.4 ± 1.5
|
< 0.001
|
7.1 ± 1.2
|
7.3 ± 1.3
|
< 0.001
|
7.2 ± 1.2
|
7.3 ± 1.3
|
< 0.001
|
Triglycerides ≥150 mg/dl |
17,380 (33.8%)
|
1916 (52.0%)
|
< 0.001
|
10,902 (26.1%)
|
4792 (42.0%)
|
< 0.001
|
4696 (21.4%)
|
5781 (33.8%)
|
< 0.001
|
HDL < 40/< 50 mg/dL (Male/Female) |
19,366 (38.3%)
|
1837 (51.1%)
|
< 0.001
|
12,780 (31.1%)
|
4939 (44.2%)
|
< 0.001
|
6188 (28.6%)
|
6998 (41.7%)
|
< 0.001
|
LDL ≥100 mg/dL |
26,449 (52.8%)
|
1593 (45.1%)
|
< 0.001
|
18,723 (45.6%)
|
4820 (43.4%)
|
< 0.001
| 10,034 (46.5%) | 7676 (45.9%) | 0.061 |
Blood Pressure ≥ 140/85 mmHg |
22,307 (47.6%)
|
1795 (54.0%)
|
< 0.001
| 21,453 (56.1%) | 5701 (56.0%) | 0.130 |
11,688 (58.8%)
|
8518 (56.6%)
|
< 0.001
|
Smokers |
8406 (25.5%)
|
459 (20.4%)
|
< 0.001
|
3612 (14.5%)
|
823 (12.2%)
|
< 0.001
|
923 (7.7%)
|
570 (6.0%)
|
< 0.001
|
Cardiovascular therapy | |||||||||
Lipid-lowering treatment |
28,831 (53.1%)
|
2571 (65.2%)
|
< 0.001
|
27,130 (61.1%)
|
8360 (67.9%)
|
< 0.001
|
12,802 (53.9%)
|
10,996 (58.1%)
|
< 0.001
|
Treatment with statins |
25,854 (47.6%)
|
2148 (54.5%)
|
< 0.001
|
25,456 (57.4%)
|
7472 (60.7%)
|
< 0.001
|
12,224 (51.5%)
|
10,188 (53.8%)
|
< 0.001
|
Treatment with fibrates |
1982 (3.7%)
|
303 (7.7%)
|
< 0.001
|
927 (2.1%)
|
576 (4.7%)
|
< 0.001
|
310 (1.3%)
|
490 (2.6%)
|
< 0.001
|
Antihypertensive treatment |
31,773 (58.5%)
|
3296 (83.6%)
|
< 0.001
|
32,412 (73.0%)
|
10,619 (86.3%)
|
< 0.001
|
18,098 (76.2%)
|
16,226 (85.8%)
|
< 0.001
|
Treatment with ACE-Is/ARBs |
27,592 (50.8%)
|
2868 (72.8%)
|
< 0.001
|
27,773 (62.6%)
|
9165 (74.5%)
|
< 0.001
|
14,992 (63.1%)
|
13,431 (71.0%)
|
< 0.001
|
Aspirin |
8470 (15.6%)
|
997 (25.3%)
|
< 0.001
|
10,745 (24.2%)
|
3533 (28.7%)
|
< 0.001
|
6079 (25.6%)
|
5460 (28.9%)
|
< 0.001
|
Antidiabetic therapy | |||||||||
Diet |
3010 (5.5%)
|
139 (3.5%)
|
< 0.001
|
2566 (5.8%)
|
520 (4.2%)
|
< 0.001
|
1262 (5.3%)
|
732 (3.9%)
|
< 0.001
|
Oral antidiabetic drugs |
37,223 (68.6%)
|
1927 (48.9%)
|
< 0.001
|
30,103 (67.8%)
|
6276 (51.0%)
|
< 0.001
|
15,565 (65.5%)
|
9441 (49.9%)
|
< 0.001
|
Oral drugs and insulin |
8685 (16.0%)
|
775 (19.7%)
|
< 0.001
|
7477 (16.8%)
|
2429 (19.7%)
|
< 0.001
| 3878 (16.3%) | 3390 (17.9%) | 0.001 |
Insulin |
5379 (9.9%)
|
1100 (27.9%)
|
< 0.001
|
4232 (9.5%)
|
3079 (25.0%)
|
< 0.001
|
3049 (12.8%)
|
5358 (28.3%)
|
< 0.001
|
Q Score | |||||||||
< 15 | 2345 (4.3%) | 189 (4.8%) | 0.259 | 1353 (3.0%) | 455 (3.7%) | 0.002 | 858 (3.6%) | 735 (3.9%) | 0.262 |
15–25 | 14,230 (26.2%) | 1145 (29.1%) | 0.002 |
10,953 (24.7%)
|
3494 (28.4%)
|
< 0.001
|
6555 (27.6%)
|
5788 (30.6%)
|
< 0.001
|
> 25 |
37,722 (69.5%)
|
2607 (66.2%)
|
< 0.001
|
32,072 (72.3%)
|
8355 (67.9%)
|
< 0.001
|
16,341 (68.8%)
|
12,398 (65.5%)
|
< 0.001
|
< 65 years
|
65–75 years
|
> 75 years
| |||||||
---|---|---|---|---|---|---|---|---|---|
ALB-
|
ALB+
|
ALB-
|
ALB+
|
ALB-
|
ALB+
| ||||
n = 43,352
|
n = 14,886
|
p
|
n = 40,556
|
n = 16,126
|
p
|
n = 28,300
|
n = 14,375
|
p
| |
Male sex |
25,532 (58.9%)
|
10,409 (69.9%)
|
< 0.001
|
21,651 (53.4%)
|
10,818 (67.1%)
|
< 0.001
|
12,721 (45.0%)
|
8159 (56.8%)
|
< 0.001
|
Age (years) |
56 ± 7
|
57 ± 7
|
< 0.001
|
70 ± 3
|
70 ± 3
|
< 0.001
|
80 ± 4
|
81 ± 4
|
< 0.001
|
Duration of diabetes (years) |
8 ± 7
|
9 ± 8
|
< 0.001
|
12 ± 9
|
13 ± 9
|
< 0.001
|
14 ± 11
|
16 ± 11
|
< 0.001
|
eGFR < 60 mL/min/1.73m2 |
2086 (4.8%)
|
1855 (12.5%)
|
< 0.001
|
7304 (18.0%)
|
5000 (31.0%)
|
< 0.001
|
11,316 (40.0%)
|
7605 (52.9%)
|
< 0.001
|
Retinopathy |
4346 (10.0%)
|
2652 (17.8%)
|
< 0.001
|
5357 (13.2%)
|
3416 (21.2%)
|
< 0.001
|
3729 (13.2%)
|
2750 (19.1%)
|
< 0.001
|
BMI (Kg/m2) |
30.1 ± 5.7
|
31.1 ± 5.9
|
< 0.001
|
29.4 ± 5.1
|
30.0 ± 5.1
|
< 0.001
|
28.3 ± 4.7
|
28.5 ± 4.7
|
< 0.001
|
HbA1c (%) |
7.2 ± 1.4
|
7.6 ± 1.6
|
< 0.001
|
7.1 ± 1.2
|
7.4 ± 1.3
|
< 0.001
|
7.1 ± 1.2
|
7.4 ± 1.3
|
< 0.001
|
Triglycerides ≥150 mg/dl |
13,144 (32.0%)
|
6152 (43.7%)
|
< 0.001
|
10,438 (27.4%)
|
5256 (34.9%)
|
< 0.001
|
6453 (24.8%)
|
4024 (30.7%)
|
< 0.001
|
HDL < 40/< 50 mg/dL (Male/Female) |
15,038 (37.3%)
|
6165 (44.4%)
|
< 0.001
|
12,114 (32.4%)
|
5605 (37.9%)
|
< 0.001
|
8308 (32.5%)
|
4878 (38.0%)
|
< 0.001
|
LDL ≥100 mg/dL |
21,368 (53.4%)
|
6674 (49.1%)
|
< 0.001
|
17,237 (46.0%)
|
6306 (42.8%)
|
< 0.001
|
12,048 (47.3%)
|
5662 (44.2%)
|
< 0.001
|
Blood Pressure ≥ 140/85 mmHg |
16,778 (45.2%)
|
7324 (56.3%)
|
< 0.001
|
18,392 (53.4%)
|
8762 (62.8%)
|
< 0.001
|
12,690 (55.1%)
|
7516 (63.2%)
|
< 0.001
|
Smokers |
6062 (23.4%)
|
2803 (29.9%)
|
< 0.001
|
2863 (12.9%)
|
1572 (16.9%)
|
< 0.001
|
869 (6.1%)
|
624 (8.4%)
|
< 0.001
|
Cardiovascular therapy | |||||||||
Lipid-lowering treatment |
22,567 (52.1%)
|
8835 (59.4%)
|
< 0.001
|
24,821 (61.2%)
|
10,669 (66.2%)
|
< 0.001
| 15,504 (54.8%) | 8294 (57.7%) | 0.072 |
Treatment with statins |
20,167 (46.5%)
|
7835 (52.6%)
|
< 0.001
|
23,040 (56.8%)
|
9888 (61.3%)
|
< 0.001
| 14,616 (51.6%) | 7796 (54.2%) | 0.217 |
Treatment with fibrates |
1616 (3.7%)
|
669 (4.5%)
|
< 0.001
| 1058 (2.6%) | 445 (2.8%) | 0.045 | 508 (1.8%) | 292 (2.0%) | 0.175 |
Antihypertensive treatment |
24,528 (56.6%)
|
10,541 (70.8%)
|
< 0.001
|
29,651 (73.1%)
|
13,380 (83.0%)
|
< 0.001
|
22,154 (78.3%)
|
12,170 (84.7%)
|
< 0.001
|
Treatment with ACE-Is/ARBs |
21,042 (48.5%)
|
9418 (63.3%)
|
< 0.001
|
25,256 (62.3%)
|
11,682 (72.4%)
|
< 0.001
|
18,282 (64.6%)
|
10,141 (70.5%)
|
< 0.001
|
Aspirin |
6536 (15.1%)
|
2931 (19.7%)
|
< 0.001
|
9751 (24.0%)
|
4527 (28.1%)
|
< 0.001
| 7468 (26.4%) | 4071 (28.3%) | 0.010 |
Antidiabetic therapy | |||||||||
Diet |
2596 (6.0%)
|
553 (3.7%)
|
< 0.001
|
2445 (6.0%)
|
641 (4.0%)
|
< 0.001
|
1502 (5.3%)
|
492 (3.4%)
|
< 0.001
|
Oral antidiabetic drugs |
29,916 (69.0%)
|
9234 (62.0%)
|
< 0.001
|
27,180 (67.0%)
|
9199 (57.0%)
|
< 0.001
|
17,437 (61.6%)
|
7569 (52.7%)
|
< 0.001
|
Oral drugs and insulin |
6320 (14.6%)
|
3140 (21.1%)
|
< 0.001
|
6365 (15.7%)
|
3541 (22.0%)
|
< 0.001
|
4416 (15.6%)
|
2852 (19.8%)
|
< 0.001
|
Insulin |
4520 (10.4%)
|
1959 (13.2%)
|
< 0.001
|
4566 (11.3%)
|
2745 (17.0%)
|
< 0.001
|
4945 (17.5%)
|
3462 (24.1%)
|
< 0.001
|
Q Score | |||||||||
< 15 |
864 (2.0%)
|
1670 (11.2%)
|
< 0.001
|
541 (1.3%)
|
1267 (7.9%)
|
< 0.001
|
449 (1.6%)
|
1144 (8.0%)
|
< 0.001
|
15–25 |
9847 (22.7%)
|
5528 (37.1%)
|
< 0.001
|
8829 (21.8%)
|
5618 (34.8%)
|
< 0.001
|
6948 (24.6%)
|
5395 (37.5%)
|
< 0.001
|
> 25 |
32,641 (75.3%)
|
7688 (51.6%)
|
< 0.001
|
31,186 (76.9%)
|
9241 (57.3%)
|
< 0.001
|
20,903 (73.9%)
|
7836 (54.5%)
|
< 0.001
|
Factors associated with low eGFR and albuminuria according to age
Overall |
p
| < 65 years |
p
| 65–75 years |
p
| > 75 years |
p
| |
---|---|---|---|---|---|---|---|---|
Model for eGFR < 60 mL/min/1.73 m
2
| ||||||||
Male sex |
0.85 (0.82–0.88)
|
< 0.001
|
0.83 (0.76–0.90)
|
< 0.001
|
0.84 (0.80–0.88)
|
< 0.001
|
0.86 (0.82–0.91)
|
< 0.001
|
Age (×5 years) |
1.81 (1.79–1.83)
|
< 0.001
|
1.75 (1.67–1.82)
|
< 0.001
|
1.90 (1.82–1.99)
|
< 0.001
|
1.77 (1.72–1.83)
|
< 0.001
|
BMI (× 5 Kg/m2) |
1.19 (1.17–1.21)
|
< 0.001
|
1.13 (1.09–1.17)
|
< 0.001
|
1.18 (1.15–1.21)
|
< 0.001
|
1.23 (1.20–1.27)
|
< 0.001
|
Albuminuria |
2.14 (2.06–2.22)
|
< 0.001
|
2.90 (2.66–3.17)
|
< 0.001
|
2.22 (2.10–2.35)
|
< 0.001
|
1.78 (1.68–1.88)
|
< 0.001
|
HbA1c (×1%) | 1.00 (0.99–1.02) | 0.839 | 1.00 (0.97–1.03) | 0.979 | 1.01 (0.99–1.03) | 0.421 | 1.00 (0.98–1.02) | 0.976 |
Triglycerides ≥150 mg/dl |
1.69 (1.63–1.76)
|
< 0.001
|
1.85 (1.70–2.02)
|
< 0.001
|
1.73 (1.64–1.83)
|
< 0.001
|
1.58 (1.49–1.67)
|
< 0.001
|
HDL < 40/< 50 mg/dL (Male/Female) |
1.41 (1.36–1.46)
|
< 0.001
|
1.34 (1.23–1.46)
|
< 0.001
|
1.39 (1.32–1.47)
|
< 0.001
|
1.48 (1.40–1.56)
|
< 0.001
|
LDL ≥100 mg/dL |
0.88 (0.86–0.91)
|
< 0.001
|
0.80 (0.74–0.87)
|
< 0.001
|
0.90 (0.85–0.94)
|
< 0.001
|
0.91 (0.87–0.96)
|
< 0.001
|
Blood Pressure ≥ 140/85 mmHg |
0.87 (0.84–0.90)
|
< 0.001
| 1.00 (0.92–1.09) | 0.969 |
0.86 (0.82–0.91)
|
< 0.001
|
0.84 (0.79–0.88)
|
< 0.001
|
Smokinga |
0.79 (0.74–0.84)
|
< 0.001
|
0.73 (0.64–0.83)
|
< 0.001
|
0.81 (0.73–0.90)
|
< 0.001
| 0.82 (0.71–0.94) | 0.004 |
Model for Albuminuria | ||||||||
Male sex |
2.09 (2.02–2.15)
|
< 0.001
|
1.94 (1.83–2.05)
|
< 0.001
|
2.30 (2.18–2.42)
|
< 0.001
|
2.05 (1.93–2.17)
|
< 0.001
|
Age (×5 years) |
1.07 (1.06–1.08)
|
< 0.001
|
1.02 (1.01–1.04)
|
0.011
|
1.08 (1.04–1.13)
|
< 0.001
|
1.16 (1.11–1.20)
|
< 0.001
|
BMI (×5 Kg/m2) |
1.11 (1.09–1.12)
|
< 0.001
|
1.14 (1.12–1.17)
|
< 0.001
|
1.11 (1.09–1.14)
|
< 0.001
| 1.05 (1.02–1.08) | 0.003 |
eGFR< 60 mL/min/1.73 m2 |
2.19 (2.11–2.27)
|
< 0.001
|
2.99 (2.74–3.27)
|
< 0.001
|
2.27 (2.14–2.40)
|
< 0.001
|
1.82 (1.72–1.93)
|
< 0.001
|
HbA1c (×1%) |
1.22 (1.20–1.23)
|
< 0.001
|
1.21 (1.19–1.23)
|
< 0.001
|
1.24 (1.21–1.27)
|
< 0.001
|
1.19 (1.16–1.22)
|
< 0.001
|
Triglycerides ≥150 mg/dl |
1.26 (1.22–1.31)
|
< 0.001
|
1.40 (1.33–1.48)
|
< 0.001
|
1.19 (1.13–1.26)
|
< 0.001
|
1.19 (1.11–1.27)
|
< 0.001
|
HDL < 40/< 50 mg/dL (Male/Female) |
1.19 (1.15–1.23)
|
< 0.001
|
1.18 (1.11–1.24)
|
< 0.001
|
1.21 (1.14–1.28)
|
< 0.001
|
1.18 (1.11–1.26)
|
< 0.001
|
LDL ≥100 mg/dL |
0.92 (0.89–0.95)
|
< 0.001
|
0.89 (0.85–0.94)
|
< 0.001
| 0.94 (0.89–0.98) | 0.010 | 0.92 (0.87–0.97) | 0.002 |
Blood Pressure ≥ 140/85 mmHg |
1.47 (1.42–1.51)
|
< 0.001
|
1.49 (1.41–1.57)
|
< 0.001
|
1.45 (1.37–1.52)
|
< 0.001
|
1.47 (1.38–1.56)
|
< 0.001
|
Smokinga |
1.60 (1.52–1.68)
|
< 0.001
|
1.58 (1.47–1.70)
|
< 0.001
|
1.68 (1.54–1.84)
|
< 0.001
|
1.55 (1.35–1.79)
|
< 0.001
|